Vaksinasi COVID-19 ditinjau dari Perspektif Ekonomi Kesehatan

https://doi.org/10.35912/jimi.v2i1.1276
Published: Nov 1, 2022

Abstract:

Purpose: To describe the COVID-19 vaccination from the aspects of cost-effectiveness, monetary benefit, fiscal modeling, and health efficacy.

Method: It is a systematic literature review. This systematic review described COVID-19 vaccination effectiveness from health economic perspectives, cost-effectiveness, monetary benefit, fiscal modeling, and heath efficacy. Literatures were taken from PubMed and Science Direct. There were 10 papers from PubMed, 3 papers from Science Direct, and 186 from Google Scholar at the beginning. After being selected for title, abstract and full content, 11 journals were left. PRISMA guidelines were used. Inclusion criteria are review and research articles. The excluded articles that were not peer-reviewed and unavailable full-text paper. Articles were read twice to reduce the bias. The selected articles were summarized and narrated descriptively.

Results: Results revealed that vaccination is cost-effective and cost-saving based on economic model analysis such as QALY rate, global COVID-19 VAR model, and ICER. The mortality and morbidity of the COVID-19 infection are depended on the vaccination program.

Limitations: There were only some articles included in the systematic review. Therefore, the result might be not complete and comprehensive.

Contribution: This paper can be used as a review for implementing the vaccination program based on the effectiveness from health economic perspectives.

Keywords:
1. COVID-19 vaccination
2. cost-effectiveness
3. fiscal modeling
4. heath efficacy
5. monetary benefit
Authors:
Yuliana Yuliana
View PDF
How to Cite
Yuliana, Y. (2022). Vaksinasi COVID-19 ditinjau dari Perspektif Ekonomi Kesehatan . Jurnal Ilmu Medis Indonesia, 2(1), 45–54. https://doi.org/10.35912/jimi.v2i1.1276
Download Citation
  1. Endnote/Zotero/Mendeley (RIS)
  2. BibTeX

Downloads

Download data is not yet available.
Issue & Section
Vol. 2 No. 1 (2022): September
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

References

    Arndt, Channing, Rob Davies, Sherwin Gabriel, Laurence Harris, Konstantin Makrelov, Sherman Robinson, Stephanie Levy, Witness Simbanegavi, Dirk Van Seventer, and Lillian Anderson. 2020. “Covid-19 Lockdowns, Income Distribution, and Food Security: An Analysis for South Africa.” Global Food Security 26(100410):1–6.

    Bartsch, Sarah M., Kelly J. O. Shea, Marie C. Ferguson, Maria Elena Bottazzi, Patrick T. Wedlock, Ulrich Strych, James A. Mckinnell, Sheryl S. Siegmund, Sarah N. Cox, Peter J. Hotez, and Bruce Y. Lee. 2020. “Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention.” American Journal of Preventive Medicine 59(4):493–503.

    Cavanaugh, Alyson M., Kevin B. Spicer, Douglas Thoroughman, Connor Glick, and Kathleen Winter. 2021. “Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination —.” Morbidity and Mortality Weekly Report 70(32):1081–83.

    Chudik, Alexander, Kamiar Mohaddes, and Mehdi Raissi. 2021. “Covid-19 Fiscal Support and Its Effectiveness.” Economics Letters 205:1–5.

    Connolly, Mark P., and Nikolaos Kotsopoulos. 2020. “Estimating the Fiscal Consequences of National Immunization Programs Using a ‘ Government Perspective ’ Public Economic Framework.” Vaccines 8(495):1–11.

    Du, Zhanwei, Lin Wang, Yuan Bai, Xutong Wang, Abhishek Pandey, Meagan C. Fitzpatrick, Matteo Chinazzi, Benjamin J. Cowling, and Lauren Ancel. 2022. “Articles Cost-Effective Proactive Testing Strategies during COVID-19 Mass Vaccination?: A Modelling Study.” The Lancet Regional Health - Americas 8:1–10.

    Du, Zhanwei, Lin Wang, Abhishek Pandey, Wey Wen Lim, Matteo Chinazzi, Ana Pastore, Eric H. Y. Lau, Peng Wu, Anup Malani, Sarah Cobey, and Benjamin J. Cowling. 2019. “Modeling Comparative Cost-Effectiveness of SARS-CoV-2 Vaccine Dose Fractionation in India.” Nature Medicine 1–18.

    Hagens, Arnold, Ahmet Ça?gkan Inkaya, Kasirga Yildirak, Mesut Sancar, Jurjen Van Der Schans, Aylin Acar Sancar, Serhat Ünal, Maarten Postma, and Selen Yegenoglu. 2021. “COVID-19 Vaccination Scenarios?: A Cost-Effectiveness Analysis for Turkey.” Vaccines 9(399):1–19.

    Jiang, Yawen, Dan Cai, and Si Shi. 2022. “Economic Evaluations of Inactivated COVID-19 Vaccines in Six Western Paci Fi c and South East Asian Countries and Regions?: A Modeling Study.” Infectious Disease Modelling 7(1):109–21.

    Kohli, Michele, Michael Maschio, Debbie Becker, and Milton C. Weinstein. 2021. “The Potential Public Health and Economic Value of a Hypothetical COVID-19 Vaccine in the United States?: Use of Cost-Effectiveness Modeling to Inform Vaccination Prioritization.” Vaccine 39(7):1157–64.

    Mallapaty, Smriti. 2021. “China’s Covid Vaccines Have Been Crucial: Now Immunity Is Waning.” Nature 598:398–99.

    Marco-franco, Julio Emilio, Pedro Pita-barros, Silvia Gonz, Iryna Sabat, and David Vivas-consuelo. 2021. “Simplified Mathematical Modelling of Uncertainty?: Cost-Effectiveness of COVID-19 Vaccines in Spain.” Mathematics 9(566):1–15.

    Neumann, By Peter J., Joshua T. Cohen, David D. Kim, and Daniel A. Ollendorf. 2021. “Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic.” Health Affairs 40(1):53–61.

    Volodymyrovych, Tsekhmister Yaroslav, Stepanenko Viktor Ivanovich, Konovalova Tetiana, and Tsekhmister Bogdan Yaroslavovych. 2021. “Pharmaco Economics Analysis of COVID-19 Vaccines in Ukraine.” Journal of Pharmaceutical Research International 33(May):140–47.

    Wouters, Olivier J., Kenneth C. Shadlen, Maximilian Salcher-konrad, Andrew J. Pollard, Heidi J. Larson, Yot Teerawattananon, and Mark Jit. 2021. “Health Policy Challenges in Ensuring Global Access to COVID-19 Vaccines: Production, Affordability, Allocation, and Deployment.” The Lancet 397(10278):1023–34.

  1. Arndt, Channing, Rob Davies, Sherwin Gabriel, Laurence Harris, Konstantin Makrelov, Sherman Robinson, Stephanie Levy, Witness Simbanegavi, Dirk Van Seventer, and Lillian Anderson. 2020. “Covid-19 Lockdowns, Income Distribution, and Food Security: An Analysis for South Africa.” Global Food Security 26(100410):1–6.
  2. Bartsch, Sarah M., Kelly J. O. Shea, Marie C. Ferguson, Maria Elena Bottazzi, Patrick T. Wedlock, Ulrich Strych, James A. Mckinnell, Sheryl S. Siegmund, Sarah N. Cox, Peter J. Hotez, and Bruce Y. Lee. 2020. “Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention.” American Journal of Preventive Medicine 59(4):493–503.
  3. Cavanaugh, Alyson M., Kevin B. Spicer, Douglas Thoroughman, Connor Glick, and Kathleen Winter. 2021. “Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination —.” Morbidity and Mortality Weekly Report 70(32):1081–83.
  4. Chudik, Alexander, Kamiar Mohaddes, and Mehdi Raissi. 2021. “Covid-19 Fiscal Support and Its Effectiveness.” Economics Letters 205:1–5.
  5. Connolly, Mark P., and Nikolaos Kotsopoulos. 2020. “Estimating the Fiscal Consequences of National Immunization Programs Using a ‘ Government Perspective ’ Public Economic Framework.” Vaccines 8(495):1–11.
  6. Du, Zhanwei, Lin Wang, Yuan Bai, Xutong Wang, Abhishek Pandey, Meagan C. Fitzpatrick, Matteo Chinazzi, Benjamin J. Cowling, and Lauren Ancel. 2022. “Articles Cost-Effective Proactive Testing Strategies during COVID-19 Mass Vaccination?: A Modelling Study.” The Lancet Regional Health - Americas 8:1–10.
  7. Du, Zhanwei, Lin Wang, Abhishek Pandey, Wey Wen Lim, Matteo Chinazzi, Ana Pastore, Eric H. Y. Lau, Peng Wu, Anup Malani, Sarah Cobey, and Benjamin J. Cowling. 2019. “Modeling Comparative Cost-Effectiveness of SARS-CoV-2 Vaccine Dose Fractionation in India.” Nature Medicine 1–18.
  8. Hagens, Arnold, Ahmet Ça?gkan Inkaya, Kasirga Yildirak, Mesut Sancar, Jurjen Van Der Schans, Aylin Acar Sancar, Serhat Ünal, Maarten Postma, and Selen Yegenoglu. 2021. “COVID-19 Vaccination Scenarios?: A Cost-Effectiveness Analysis for Turkey.” Vaccines 9(399):1–19.
  9. Jiang, Yawen, Dan Cai, and Si Shi. 2022. “Economic Evaluations of Inactivated COVID-19 Vaccines in Six Western Paci Fi c and South East Asian Countries and Regions?: A Modeling Study.” Infectious Disease Modelling 7(1):109–21.
  10. Kohli, Michele, Michael Maschio, Debbie Becker, and Milton C. Weinstein. 2021. “The Potential Public Health and Economic Value of a Hypothetical COVID-19 Vaccine in the United States?: Use of Cost-Effectiveness Modeling to Inform Vaccination Prioritization.” Vaccine 39(7):1157–64.
  11. Mallapaty, Smriti. 2021. “China’s Covid Vaccines Have Been Crucial: Now Immunity Is Waning.” Nature 598:398–99.
  12. Marco-franco, Julio Emilio, Pedro Pita-barros, Silvia Gonz, Iryna Sabat, and David Vivas-consuelo. 2021. “Simplified Mathematical Modelling of Uncertainty?: Cost-Effectiveness of COVID-19 Vaccines in Spain.” Mathematics 9(566):1–15.
  13. Neumann, By Peter J., Joshua T. Cohen, David D. Kim, and Daniel A. Ollendorf. 2021. “Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic.” Health Affairs 40(1):53–61.
  14. Volodymyrovych, Tsekhmister Yaroslav, Stepanenko Viktor Ivanovich, Konovalova Tetiana, and Tsekhmister Bogdan Yaroslavovych. 2021. “Pharmaco Economics Analysis of COVID-19 Vaccines in Ukraine.” Journal of Pharmaceutical Research International 33(May):140–47.
  15. Wouters, Olivier J., Kenneth C. Shadlen, Maximilian Salcher-konrad, Andrew J. Pollard, Heidi J. Larson, Yot Teerawattananon, and Mark Jit. 2021. “Health Policy Challenges in Ensuring Global Access to COVID-19 Vaccines: Production, Affordability, Allocation, and Deployment.” The Lancet 397(10278):1023–34.